Matches in SemOpenAlex for { <https://semopenalex.org/work/W2589160043> ?p ?o ?g. }
Showing items 1 to 78 of
78
with 100 items per page.
- W2589160043 abstract "329 Background: Surgical therapy remains the only curative modality for pancreatic cancer, though survival remains quite poor even for patients with resected early stage disease. Better (neo) adjuvant therapies are needed to improve resectability rates for patients with borderline resectable pancreatic cancer and to prevent recurrence following resection. We undertook this pilot study to determine the safety of accelerated fraction radiotherapy (AFRT) with capecitabine in such patients. Methods: Eligible patients have histologically confirmed borderline resectable adenocarcinoma of the pancreas as defined by the MD Anderson categories of vascular involvement, indeterminate metastatic disease, borderline performance status; normal organ function; and no prior therapy for pancreatic cancer. Radiation is given as external beam radiation therapy to a dose of 50 Gy delivered in 20, 2.5 Gy fractions Mon-Fri using IMRT. If insurance denied IMRT, 3D conformal techniques with daily image guidance is permitted. Capecitabine is delivered as 825mg/m 2 BID on radiation days. The primary outcome is to determine the frequency of treatment-related adverse events (AE). Planned enrollment is 40 pts. Results: 10 pts have enrolled to date. 8/10 received IMRT. This regimen has been exceedingly tolerable. Lymphopenia is the most common AE (n=10), grade 3-4 n=6. Other common toxicities were hyponatremia (n=6), fatigue (n=5). Grade 3 AE occurred in 8 pts, grade 4 in 3 patients. One pt had hemorrhage from a radiation induced gastric ulcer complicated by an MI. 5/10 pts had stable disease and were resected and 4/5 had an R0 resection. In the remaining 5/10 patients, disease progressed outside the pancreas and they are receiving palliative therapy. Conclusions: The combination of AFRT and capecitabine was well tolerated. Xenograft models derived from these patients’ tumors are being used to study molecular mechanisms of treatment resistance that could be targeted in a follow up phase II study building on this platform." @default.
- W2589160043 created "2017-03-03" @default.
- W2589160043 creator A5005453392 @default.
- W2589160043 creator A5020089431 @default.
- W2589160043 creator A5025178739 @default.
- W2589160043 creator A5055680737 @default.
- W2589160043 creator A5077902939 @default.
- W2589160043 creator A5085450236 @default.
- W2589160043 creator A5085949674 @default.
- W2589160043 date "2012-02-01" @default.
- W2589160043 modified "2023-10-16" @default.
- W2589160043 title "Accelerated fraction radiotherapy with concomitant capecitabine as neoadjuvant therapy of borderline resectable pancreatic cancer." @default.
- W2589160043 doi "https://doi.org/10.1200/jco.2012.30.4_suppl.329" @default.
- W2589160043 hasPublicationYear "2012" @default.
- W2589160043 type Work @default.
- W2589160043 sameAs 2589160043 @default.
- W2589160043 citedByCount "3" @default.
- W2589160043 countsByYear W25891600432012 @default.
- W2589160043 countsByYear W25891600432019 @default.
- W2589160043 crossrefType "journal-article" @default.
- W2589160043 hasAuthorship W2589160043A5005453392 @default.
- W2589160043 hasAuthorship W2589160043A5020089431 @default.
- W2589160043 hasAuthorship W2589160043A5025178739 @default.
- W2589160043 hasAuthorship W2589160043A5055680737 @default.
- W2589160043 hasAuthorship W2589160043A5077902939 @default.
- W2589160043 hasAuthorship W2589160043A5085450236 @default.
- W2589160043 hasAuthorship W2589160043A5085949674 @default.
- W2589160043 hasConcept C121608353 @default.
- W2589160043 hasConcept C126322002 @default.
- W2589160043 hasConcept C126838900 @default.
- W2589160043 hasConcept C141071460 @default.
- W2589160043 hasConcept C143998085 @default.
- W2589160043 hasConcept C146357865 @default.
- W2589160043 hasConcept C151730666 @default.
- W2589160043 hasConcept C197934379 @default.
- W2589160043 hasConcept C2777909004 @default.
- W2589160043 hasConcept C2778764654 @default.
- W2589160043 hasConcept C2779384505 @default.
- W2589160043 hasConcept C2780210213 @default.
- W2589160043 hasConcept C2781413609 @default.
- W2589160043 hasConcept C509974204 @default.
- W2589160043 hasConcept C526805850 @default.
- W2589160043 hasConcept C71924100 @default.
- W2589160043 hasConcept C86803240 @default.
- W2589160043 hasConceptScore W2589160043C121608353 @default.
- W2589160043 hasConceptScore W2589160043C126322002 @default.
- W2589160043 hasConceptScore W2589160043C126838900 @default.
- W2589160043 hasConceptScore W2589160043C141071460 @default.
- W2589160043 hasConceptScore W2589160043C143998085 @default.
- W2589160043 hasConceptScore W2589160043C146357865 @default.
- W2589160043 hasConceptScore W2589160043C151730666 @default.
- W2589160043 hasConceptScore W2589160043C197934379 @default.
- W2589160043 hasConceptScore W2589160043C2777909004 @default.
- W2589160043 hasConceptScore W2589160043C2778764654 @default.
- W2589160043 hasConceptScore W2589160043C2779384505 @default.
- W2589160043 hasConceptScore W2589160043C2780210213 @default.
- W2589160043 hasConceptScore W2589160043C2781413609 @default.
- W2589160043 hasConceptScore W2589160043C509974204 @default.
- W2589160043 hasConceptScore W2589160043C526805850 @default.
- W2589160043 hasConceptScore W2589160043C71924100 @default.
- W2589160043 hasConceptScore W2589160043C86803240 @default.
- W2589160043 hasLocation W25891600431 @default.
- W2589160043 hasOpenAccess W2589160043 @default.
- W2589160043 hasPrimaryLocation W25891600431 @default.
- W2589160043 hasRelatedWork W2068460136 @default.
- W2589160043 hasRelatedWork W2136224372 @default.
- W2589160043 hasRelatedWork W2336726368 @default.
- W2589160043 hasRelatedWork W2377069007 @default.
- W2589160043 hasRelatedWork W2561316101 @default.
- W2589160043 hasRelatedWork W2652729657 @default.
- W2589160043 hasRelatedWork W2993574470 @default.
- W2589160043 hasRelatedWork W4229993127 @default.
- W2589160043 hasRelatedWork W4240544598 @default.
- W2589160043 hasRelatedWork W2187801383 @default.
- W2589160043 isParatext "false" @default.
- W2589160043 isRetracted "false" @default.
- W2589160043 magId "2589160043" @default.
- W2589160043 workType "article" @default.